Publications

Publications

Analysis of intraprostatic therapeutic effects in prostate cancer patients using [(11)C]-choline pet/ct after external-beam radiation therapy.

By:
Contributors: Melinda Wuest, PhD, Matthew Parliament, MD, FRCPC, Nawaid Usmani, MD, FRCPC
Curr Oncol. 2013 Apr;20(2):104-10. doi: 10.3747/co.20.1217.

Abstract

PURPOSE:

The objective of the present study was to analyze, with relatively high sensitivity and specificity, uptake properties of [(11)C]-choline in prostate cancer patients by means of positron-emission tomography (pet)/computed tomography (ct) imaging using objectively defined pet parameters to test for statistically significant changes before, during, and after external-beam radiation therapy (ebrt) and to identify the time points at which the changes occur.

METHODS:

The study enrolled 11 patients with intermediate-risk prostate cancer treated with ebrt, who were followed for up to 12 months after ebrt. The [(11)C]-choline pet scans were performed before treatment (baseline); at weeks 4 and 8 of ebrt; and at 1, 2, 3, 6, and 12 months after ebrt.

RESULTS:

Analysis of [(11)C]-choline uptake in prostate tissue before treatment resulted in a maximum standardized uptake value (suvmax) of 4.0 ± 0.4 (n = 11) at 40 minutes after injection. During week 8 of ebrt, the suvmax declined to 2.9 ± 0.1 (n = 10, p < 0.05). At 2 and 12 months after ebrt, suvmax values were 2.3 ± 0.3 (n = 10, p < 0.01) and 2.2 ± 0.2 (n = 11, p < 0.001) respectively, indicating that, after ebrt, maximum radiotracer uptake in the prostate was significantly reduced. Similar effects were observed when analyzing the tumour:muscle ratio (tmr). The tmr declined from 7.4 ± 0.6 (n = 11) before ebrt to 6.1 ± 0.4 (n = 11, nonsignificant) during week 8 of ebrt, to 5.6 ± 0.03 (n = 11, p < 0.05) at 2 months after ebrt, and to 4.4 ± 0.4 (n = 11, p < 0.001) at 12 months after ebrt.

CONCLUSIONS:

Our study demonstrated that intraprostatic [(11)C]-choline uptake in the 11 analyzed prostate cancer patients significantly declined during and after ebrt. The pet parameters SUVmax and tmr also declined significantly. These effects can be detected during radiation therapy and up to 1 year after therapy. The prognostic value of these early and statistically significant changes in intraprostatic [(11)C]-choline pet avidity during and after ebrt are not yet established. Future studies are indicated to correlate changes in [(11)C]-choline uptake parameters with long-term biochemical recurrence to further evaluate [(11)C]-choline pet changes as a possible, but currently unproven, biomarker of response.

 PubMed

Download PDF

 

Prostate Cancer Canada’s Step Up Challenge 2019!

Prostate Cancer Canada’s Step Up Challenge 2019 pits endurance and drive against multistory office tower stairwells and gravity to raise funds for local prostate cancer research projects and initiatives in four Canadian cities. Heroic participants challenged the stairs in Toronto and Calgary on March 3rd, still to come is Vancouver on March 10th and Edmonton on March 17th (St. Patricks day!).

Congratulations to Calgary’s Step Up Challenge event participants who raised 111% of their $95 000 goal! These proceeds will support Dr. Tarek Bismar’s team at the University of Calgary. They are using blood samples from men with slow-growing prostate cancer that has not spread outside the prostate to determine if their disease is likely to advance. Learn more about this project from APCaRI and the Prostate cancer Collaborative Research Alliance.

Edmonton’s Step Up Challenge event is actively raising funds to support Dr. Kerry Courneya’s team at the University of Alberta, with 30% of the $65 000 goal reached currently. Dr. Courneya is a Professor and Canada Research Chair in Physical Activity and Cancer and Director of The Behavioral Medicine Laboratory and Fitness Center. This project is being led by doctoral student Dong-woo (Derek) Kang and will study whether exercise can reduce tumour growth and anxiety for men on active surveillance. Learn more about this project that could contribute to delaying, or even eliminating, the need for treatment from the Behavioral Medicine Laboratory and Fitness Center.

Dr. Kerry Courneya

ERASE-Scientific-Abstract

Please support the Edmonton Step Up Challenge 2019 as either a participant, or donor, or both!
The Lewis lab has entered Team Nanosteps into the challenge, check out our fundraising page and support the team by clicking on this link and making a secure online donation using your credit card.

Kerry Courneya’s Behavioral Medicine Lab team is also hitting the stairs, please click here to go to their Step Up Challenge team page to sponsor them with a donation as well!

Thanks in advance for any support you are able to provide. Get your runners and see you on March 17th!

- Perrin Beatty